Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study
- Author
- HEIGENER, David F1 ; WU, Yi-Long2 ; VAN ZANDWIJK, Nico3 ; MALI, Pekka4 ; HORWOOD, Keith5 ; RECK, Martin1
[1] Hospital Grosshansdorf, Grosshansdorf, Germany
[2] Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
[3] University of Sydney, Bernie Banton Centre, Concord, Australia
[4] Turku University Hospital, Turku, Finland
[5] John Flynn Private Hospital, Gold Coast, Australia - Source
Lung cancer. 2011, Vol 74, Num 2, pp 274-279, 6 p ; ref : 24 ref
- CODEN
- LUCAE5
- ISSN
- 0169-5002
- Scientific domain
- Medical oncology; Pneumology
- Publisher
- Elsevier, Oxford
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Author keyword
- Efficacy Erlotinib NSCLC Safety Second-line
- Keyword (fr)
- Cancérologie Carcinome non petite cellule bronchopulmonaire Carcinome non petite cellule Efficacité Erlotinib Homme Pathologie de l'appareil respiratoire Pneumologie Sous groupe Sécurité Cancer Pathologie des bronches Pathologie des poumons Tumeur maligne
- Keyword (en)
- Cancerology non-small cell lung carcinoma Non small cell carcinoma Efficiency Erlotinib Human Respiratory disease Pneumology Subgroup Safety Cancer Bronchus disease Lung disease Malignant tumor
- Keyword (es)
- Cancerología Carcinoma no pequeňa célula bronchopulmonar Carcinoma no pequeña célula Eficacia Erlotinib Hombre Aparato respiratorio patología Neumología Subgrupo Seguridad Cáncer Bronquio patología Pulmón patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pulmonology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 24636074
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.lungcan.2011.02.017 
https://dx.doi.org/10.1016/j.lungcan.2011.02.017
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.lungcan.2011.02.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Lung cancer\";s:9:\"\u0000*\u0000stitle\";s:11:\"Lung cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"274\";s:8:\"\u0000*\u0000epage\";s:3:\"279\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-5002\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HEIGENER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:11:\"WU, Yi-Long\";i:1;s:18:\"VAN ZANDWIJK, Nico\";i:2;s:11:\"MALI, Pekka\";i:3;s:14:\"HORWOOD, Keith\";i:4;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LUCAE5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.lungcan.2011.02.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Lung cancer\";s:9:\"\u0000*\u0000stitle\";s:11:\"Lung cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"274\";s:8:\"\u0000*\u0000epage\";s:3:\"279\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-5002\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HEIGENER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:11:\"WU, Yi-Long\";i:1;s:18:\"VAN ZANDWIJK, Nico\";i:2;s:11:\"MALI, Pekka\";i:3;s:14:\"HORWOOD, Keith\";i:4;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LUCAE5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.lungcan.2011.02.017\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.lungcan.2011.02.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Lung cancer\";s:9:\"\u0000*\u0000stitle\";s:11:\"Lung cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"274\";s:8:\"\u0000*\u0000epage\";s:3:\"279\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-5002\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HEIGENER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:11:\"WU, Yi-Long\";i:1;s:18:\"VAN ZANDWIJK, Nico\";i:2;s:11:\"MALI, Pekka\";i:3;s:14:\"HORWOOD, Keith\";i:4;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LUCAE5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.lungcan.2011.02.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Lung cancer\";s:9:\"\u0000*\u0000stitle\";s:11:\"Lung cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"274\";s:8:\"\u0000*\u0000epage\";s:3:\"279\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-5002\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HEIGENER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:11:\"WU, Yi-Long\";i:1;s:18:\"VAN ZANDWIJK, Nico\";i:2;s:11:\"MALI, Pekka\";i:3;s:14:\"HORWOOD, Keith\";i:4;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LUCAE5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.lungcan.2011.02.017\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:9:\"\u0000*\u0000jtitle\";s:11:\"Lung cancer\";s:9:\"\u0000*\u0000stitle\";s:11:\"Lung cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2011\";s:9:\"\u0000*\u0000volume\";s:2:\"74\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"274\";s:8:\"\u0000*\u0000epage\";s:3:\"279\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0169-5002\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"HEIGENER\";s:10:\"\u0000*\u0000aufirst\";s:7:\"David F\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:11:\"WU, Yi-Long\";i:1;s:18:\"VAN ZANDWIJK, Nico\";i:2;s:11:\"MALI, Pekka\";i:3;s:14:\"HORWOOD, Keith\";i:4;s:12:\"RECK, Martin\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"LUCAE5\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:114:\"Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study\";s:8:\"\u0000*\u0000place\";s:6:\"Oxford\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
